CAJ | 학술논문

目的观察联合应用阿托伐他汀与依折麦布对冠状动脉粥样硬化性心脏病(简称冠心病)合并高胆固醇血症患者颈动脉粥样硬化斑块的影响.方法 92例合并颈动脉粥样硬化的冠心病患者,分为对照组(单用阿托伐他汀)及联合组(阿托伐他汀及依折麦布),疗程12个月.测定治疗前后颈动脉硬化的相关指标,血脂、高敏C反应蛋白(hs-CRP)及基质金属蛋白酶-9(MMP-9)水平.结果联合组治疗12个月后颈动脉斑块面积明显减小[(19.12±2.56) mm2比(25.76±1.01) mm2,P＜0.05].两组治疗后比较,颈动脉斑块面积[(19.12±2.56) mm2比(23.43±2.75)mm2,P＜0.05]、不斑块稳定率(79.67％比85.84％,P＜0.05)、低密度脂蛋白胆固醇(LDL-C)[(2.34±0.56) mm2比(2.75 ±0.58) mmol/L,P ＜0.01]、hs-CRP[(3.18 ±1.24) mg/L比(4.07±1.65) mg/L,P＜0.0l]及MMP-9水平[(129.25±40.71)μg/L比(218.92±60.34)μg/L,P＜0.01]差异有统计学意义.结论联合应用阿托伐他汀与依折麦布,能使LDL-C、hsCRP、MMP-9水平进一步降低,对高胆固醇血症合并冠心病患者颈动脉硬化进展有一定影响.
목적 관찰연합응용아탁벌타정여의절맥포대관상동맥죽양경화성심장병(간칭관심병)합병고담고순혈증환자경동맥죽양경화반괴적영향.방법 92례합병경동맥죽양경화적관심병환자,분위대조조(단용아탁벌타정)급연합조(아탁벌타정급의절맥포),료정12개월.측정치료전후경동맥경화적상관지표,혈지、고민C반응단백(hs-CRP)급기질금속단백매-9(MMP-9)수평.결과 연합조치료12개월후경동맥반괴면적명현감소[(19.12±2.56) mm2비(25.76±1.01) mm2,P＜0.05].량조치료후비교,경동맥반괴면적[(19.12±2.56) mm2비(23.43±2.75)mm2,P＜0.05]、불반괴은정솔(79.67％비85.84％,P＜0.05)、저밀도지단백담고순(LDL-C)[(2.34±0.56) mm2비(2.75 ±0.58) mmol/L,P ＜0.01]、hs-CRP[(3.18 ±1.24) mg/L비(4.07±1.65) mg/L,P＜0.0l]급MMP-9수평[(129.25±40.71)μg/L비(218.92±60.34)μg/L,P＜0.01]차이유통계학의의.결론 연합응용아탁벌타정여의절맥포,능사LDL-C、hsCRP、MMP-9수평진일보강저,대고담고순혈증합병관심병환자경동맥경화진전유일정영향.
Objective To observe the effects of atorvastatin combined with ezetimibe on carotid atherosclerosis in patients with hypercholesterolemia.Methods A total of 92 hypercholesterolemic patients complicated with coronary artery disease were divided into control group (atorvastatin used alone) and combined treatment group (atorvastatin combined with ezetimibe) and treated for 12 months.Carotid atherosclerosis-related indicators including blood lipid,high-sensitivity C-reactive protein (hs-CRP) and matrix metalloproteinases-9 (MMP-9) were detected before and after treatment.Results After treatment,the plaque area [(19.12 ±2..56) mm2 vs.(23.43 ±2.75)mm2,P ＜0.05],the ratio of unstable carotid atherosclerotic plaques (79.67％ vs.85.84％,P ＜ 0.05),serum level of low density lipoprotein cholesterol (LDL-C)[(2.34±0.56) mm2 vs.(2.75 ±0.58) mmol/L,P＜0.01],MMP-9 [(129.25 ±40.71) μg/L vs.(218.92±60.34) μg/L,P＜0.01] and hs-CRP [(3.18±1.24) mg/L vs.(4.07 ±1.65) mg/L,P＜0.O1] showed significant difference between combined treatment group and control group.The plaque area was decreased significantly in combined treatment group as compared with that before treatment [(19.12 ±2.56) mm2 vs.(25.76± 1.01) mm2,P＜0.05].Conclusion Combination of atorvastatin with ezetimibe could further decrease LDL-C,MMP-9 and hs-CRP levels and have certain effects on the progression of carotid atherosclerosis in hypereholesterolemic patients complicated with coronary artery disease.